Therapeutic area intelligence for Type 2 Diabetes Mellitus with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

Gilead →

Assets

Endoscopic →

Recent signals(2)

ClinicalJuly 27, 2026

Gilead's GS-4571 Study Targets Safety and Pharmacokinetics in T2DM and Obesity

Gilead Sciences is conducting a clinical study to evaluate the safety and pharmacokinetics of GS-4571 in various participant groups, including those with Type 2 Diabetes Mellitus.

ClinicalJuly 22, 2026

Endoscopic duodenal therapy shows promise for early Type 2 DM treatment

A study is evaluating the efficacy and safety of endoscopic duodenal re-cellularization therapy for early treatment of Type 2 DM.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Type 2 Diabetes Mellitus →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.